

Alberta Drug Benefit List (ADBL) interim update now available online

Please be advised that the **September 1, 2020**, updates to the *Alberta Drug Benefit List (ADBL)* has been posted online at www.ab.bluecross.ca/dbl/publications.php.

Please refer to the September 1, 2020, updates for complete listings of products available by special authorization, products available by step therapy/special authorization, products with changes to criteria for coverage, added products, new established interchangeable groupings, least cost alternative (LCA) price changes, products with a price change and discontinued listings.

Please note that the online Interactive Drug Benefit List (iDBL) at www.ab.bluecross.ca/dbl/idbl_main1.php is a near real-time application, and as such, contains the most up-to-date information.

Removal of temporary benefit from the Alberta Drug Benefit List (ADBL)

Due to the shortage of Methotrexate (Preserved) 25 mg/ml Injection USP (DIN 02398427) manufactured Sandoz Canada Inc. and Methotrexate Sodium (Preserved) 25 mg/ml Injection (DIN 02182777) manufactured by Pfizer Canada ULC, Methotrexate 25 mg/ml Injection Syringe BP (DIN 02422204) manufactured by Pharmascience Inc. was added as a temporary benefit for the *ADBL*.

Pfizer Canada ULC has advised Alberta Blue Cross that the shortage of Methotrexate Sodium (Preserved) 25 mg/ml Injection (DIN 02182777) has been resolved. These products were removed from the Critical Supply Product List **August 13, 2020**.

As a result, Methotrexate 25 mg/ml Injection Syringe BP (DIN 02422204) will no longer be considered a temporary benefit for the *ADBL* after **September 14, 2020**.

Product supply shortages addressed for the *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Accord Healthcare Inc. and Apotex Inc. that the shortages for Ach-Olmesartan HCTZ 40 mg/25 mg Tablet (DIN 02468964) and Apo-Olmesartan/HCTZ 40 mg/25 mg Tablet (DIN 02453622) respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 14, 2020**. The following grouping was removed from the Critical Supply Product List **August 13, 2020**.

OLMESARTAN MEDOXOMIL/ HYDROCHLOROTHIAZIDE

40 MG / 25 MG TABLET

00002468964	ACH-OLMESARTAN HCTZ	AHI	\$ 0.3019
00002443139	ACT OLMESARTAN HCT	APH	\$ 0.3019
00002453622	APO-OLMESARTAN HCTZ	APX	\$ 0.3019
00002476509	AURO-OLMESARTAN HCTZ	AUR	\$ 0.3019
00002319632	OLMETEC PLUS	MFC	\$ 1.1441

Alberta Blue Cross has been advised by Accord Healthcare Inc. and Apotex Inc. that the shortages for Ach-Olmesartan HCTZ 20 mg/12.5 mg Tablet (DIN 02468948) and Apo-Olmesartan/HCTZ 20 mg/12.5 mg Tablet (DIN 02453606) respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 21, 2020**. The following grouping was removed from the Critical Supply Product List **August 21, 2020**.

OLMESARTAN MEDOXOMIL/ HYDROCHLOROTHIAZIDE

20 MG / 12.5 MG TABLET

00002468948	ACH-OLMESARTAN HCTZ	AHI	\$ 0.3019
00002443112	ACT OLMESARTAN HCT	APH	\$ 0.3019
00002453606	APO-OLMESARTAN/HCTZ	APX	\$ 0.3019
00002476487	AURO-OLMESARTAN HCTZ	AUR	\$ 0.3019
00002319616	OLMETEC PLUS	MFC	\$ 1.1441

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit ab.bluecross.ca/providers/pharmacy-home.php

